Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation

The purpose of this vanguard trial is to test whether clients of Sun Life are willing to join in a quit smoking program that offers counselling and tobacco cessation products to all participants over a 12-month period. The study team will track the safety and usage of 3 types of cessation products as well as the effectiveness of a virtual pharmacy (i.e. cessation products delivered to participants directly from a pharmacy). The goal is to recruit a minimum of 150 participants for this Vanguard phase. The purpose of this study is to look at 3 approved smoking cessation products used in combination with counselling and virtual delivery of the smoking cessation products. The goal is to track product usage, safety, and adherence (how much of the products people use and how many counselling sessions they complete). Within the study there will also be an observational group who will not receive study medication but who will receive free virtual coaching and follow-up for smoking cessation and complete study questionnaires.

NCT Number	NCT06832085
Lead Sponsor	Ottawa Heart Institute Research Corporation Collaborators: Sun Life Assurance Company of Canada, Vita Aid Professional Therapeutics, Pillway Health Pharmacy
Conditions	Tobacco
Enrollment	150 participants
Start Date	2025-04-30
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-05